Cortexin Side Effects: Safety Signals and Warnings
Cortexin safety concerns are compound-specific. The main listed side effects are Injection site pain, Allergic reactions (rare), and Insomnia (if administered late in the day). The main warning signals are Not approved outside of Russia and CIS countries, Derived from animal brain tissue - theoretical prion disease risk, and Clinical evidence is primarily from Russian-language publications with limited independent verification.
Direct Answer
Cortexin has Phase 3-level clinical use in Russia but the evidence base is almost entirely from Russian-language publications within a regulatory context that does not meet ICH GCP standards. Independent Western replication is absent. It is not a starting point for researchers who require independently validated evidence. Of the Cognitive & Nootropic compounds, cerebrolysin has significantly more independently replicated RCT data.
- Evidence grade
- Level C
- Research status
- Phase 3
- Category
- Cognitive & Nootropic
- Best for
- Russian clinical neurology practice context only; neuroprotective polypeptide research
Reported Side Effects
- Injection site pain
- Allergic reactions (rare)
- Insomnia (if administered late in the day)
- Mild headache
Warnings
- Not approved outside of Russia and CIS countries
- Derived from animal brain tissue - theoretical prion disease risk
- Clinical evidence is primarily from Russian-language publications with limited independent verification
- Contraindicated in known hypersensitivity to animal-derived proteins
Known or Plausible Interactions
- Cerebrolysin (similar mechanism - not typically combined)
- Piracetam and other nootropics (commonly combined in Russian protocols)
- Anticonvulsants (may alter seizure threshold)
Regulatory Context
Prescription medication in Russia and CIS countries; not approved in EU, USA, or most other regions.
Evidence Snapshot
| Evidence grade | Level C |
|---|---|
| Research status | Phase 3 |
| Best supported outcomes | Cognitive Recovery After Stroke (Level C), Pediatric Neurodevelopment (Level C), and Neuroprotection (Level C) |
| Primary citation count | 2 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Cortexin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/cortexin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.